Company: LHI
Filing Date: 2025-05-23
Form Type: F-1
Source: 0001213900-25-046955
Chunk: 84

Company: Living Homeopathy International Ltd.
Filing Date: 2025-05-23
Form: F-1
Chunk 84
---
 as to whether to distribute dividends, subject to certain restrictions of Cayman Islands law. Under Cayman Islands law, our company may only pay dividends out of wither profits or share premium; provided that in no circumstances may a dividend be paid if, this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our board of directors. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on, among other things, our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in our Class A Ordinary Shares will likely depend entirely upon any future price appreciation of our Class A Ordinary Shares. There is no guarantee that our Class A Ordinary Shares will appreciate in value after this offering or even maintain the price at which you purchased the Class A Ordinary Shares. You may not realize a return on your investment in our Class A Ordinary Shares and you may even lose your entire investment in our Class A Ordinary Shares.

Substantial future sales or perceived potential sales of Class A Ordinary Shares in the public market could cause the price of the Class A Ordinary Shares to decline.

Sales of Class A Ordinary Shares in the public
market after this offering, or the perception that these sales could occur, could cause the market price of the Class A Ordinary Shares
to decline. Immediately after the completion of this offering, we will have 10,250,000 Class A Ordinary Shares outstanding,
assuming the underwriters do not exercise their over-allotment option. All Class A Ordinary Shares sold in this offering will be freely
transferable without restriction or additional registration under the Securities Act. All of our executive officers and directors and
shareholders holding 5% or more of our Class A Ordinary Shares have agreed not to sell our Class A Ordinary Shares for a period of 180
days following the effective date of this prospectus, subject to extension under specified circumstances. Class A Ordinary Shares subject
to these lock-up agreements will become eligible for sale in the public market upon expiration of these lock-up agreements, subject to
volume and other restrictions as applicable under Rules 144 and 701 under the Securities Act. To the extent